Jamieson Wellness Inc. Appoints New Board Director

Former retail executive brings grocery channel experience to the Company's Board of Directors

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL), announced today the appointment of François Vimard to the Company's Board of Directors.

"I am very pleased to welcome Mr. Vimard to our Board of Directors," said Tim Penner, Board Chair. "Mr. Vimard's deep retail background and experience shaping the Canadian grocery landscape will help Jamieson reach new heights as the leading vitamin, mineral, and supplement brand. Mr. Vimard also brings important financial and technological experience that will benefit our strategic plans as we look to expedite our growth on the global stage."

Mr. Vimard is a Chartered Professional Accountant with over 30 years of grocery retail experience, including 22 years at Empire Company, one of Canada's leading grocery companies. During his tenure at Empire, Mr. Vimard served as Chief Financial Officer from 2007 to 2014, and was appointed interim President and Chief Executive Officer in 2016, a position which he held until his retirement from the company in 2017. Mr. Vimard is a seasoned board member who currently serves as chair of the Board of Kruger Products Inc., Canada's leading manufacturer of tissue products which is publicly traded as KP Tissue Inc. (KPT.TO). He also serves on the boards of GS1 Canada, a not-for-profit company that manages global barcode standards, and Andrew Peller LTD (ADW.B), a Canadian-based winery company. He previously served on the board for Market GoodFood (FOOD), a consumer-focused meal kit delivery company.

"I am proud to be joining the Jamieson Wellness Board of Directors," said Mr. Vimard. "From my years of working closely with CPG partners in the grocery channel, I am confident that I can bring valuable insights to help Jamieson continue to build its global growth story. Jamieson is an extraordinary Canadian company with a longstanding positive reputation and an exciting future ahead. I look forward to contributing to the Board and making a positive impact for all stakeholders."

Mr. Vimard's appointment to the Jamieson Wellness Board of Directors is effective as of July 1, 2023. He will also serve as a member of the Company's Audit Committee.

About Jamieson Wellness Inc.

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness also offers a variety of VMS products under its youtheory, Progressive, Smart Solutions, Iron Vegan and Precision brands. The Company is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. For more information please visit www.jamiesonwellness.com .

Forward-Looking Information

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's future plans, goals, strategies, intentions, beliefs, objectives, economic performance or expectations. Words such as "expect", "anticipate", "intend", "may", "will", "estimate" and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 30, 2023 and under the "Risk Factors" section in the management's discussion and analysis of financial condition and results of operations of the Company filed May 4, 2023 (the "MD&A"). This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information" and "Risk Factors" within the Company's MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

Investor and Media:
Ruth Winker
Jamieson Wellness
416-705-5437
rwinker@jamiesonlabs.com

News Provided by Business Wire via QuoteMedia

JWEL:CA
The Conversation (0)
Data Safety Monitoring Board  Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

Data Safety Monitoring Board Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy... Keep Reading...
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage... Keep Reading...
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturingProgram builds on BriaCell's experience in metastatic... Keep Reading...
Stacks of white pills progressively increase in height from left to right on a solid blue background.

Moderna, Merck Shares Soar on Cancer Vaccine Trial Success

An experimental personalized mRNA vaccine developed by Moderna (NASDAQ:MRNA) and Merck & Company (NYSE:MRK) successfully prevented skin cancer from returning in a late-stage clinical trial, sending shares of both drugmakers surging on Wednesday (August 19).The Phase 3 study evaluated the... Keep Reading...
Various colorful pills and tablets spill from an orange prescription bottle onto a blue background.

Eli Lilly Surges, Novo Nordisk Slips in Weight-Loss War

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both raised their full-year profit outlooks on the back of explosive demand for GLP-1 weight-loss and diabetes treatments. But by mid-year, Eli Lilly's blockbuster injectable drugs propelled its valuation past US$1 trillion, while Novo... Keep Reading...
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell's next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components... Keep Reading...

Interactive Chart

Latest Press Releases

Related News